5 completed, 3 unknown, 1 active not recruiting, 1 not yet recruiting. 13 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 5, Unknown 3, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Arsenic Trioxide: new trials by email Literature Review of Arsenic Trioxide trials Research Report on Arsenic Trioxide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia QTX-2101 + ATRA, IV arsenic trioxide (ATO) + ATRA - Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia | Phase 3 | Recruiting | Quetzal Therapeutics | 150 | 2026-06-08 | 2026-10-30 |
| A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301) Oral ATO, IV Arsenic Trioxide, all-trans retinoic acid (ATRA) - Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia | Phase 3 | Not yet recruiting | SDK Therapeutics, Inc. | 120 | 2026-01-01 | 2025-12-29 |
| Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS) Decitabine, Arsenic Trioxide - Myelodysplastic Syndromes, P53 Mutation | Phase 3 | Withdrawn | Li Junmin | 2018-03-20 | 2023-08-16 | |
| Combination of Ibrutinib and As2O3 in the Treatment of CLL Ibrutinib combined with As2O3, ibrutinib - Leukemia, Lymphocytic, Chronic, B-Cell | Phase 3 | Unknown | Peking University People's Hospital | 70 | 2016-12-01 | 2016-04-29 |
| Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF) Realgar-Indigo naturalis formula, all-trans retinoic acid, Arsenic trioxide - Acute Promyelocytic Leukemia | Phase 3 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 110 | 2016-09-01 | 2021-09-08 |
| Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia Arsenic trioxide, Idarubicin, Cytarabine - Acute Promyelocytic Leukemia | Phase 3 | Completed | Technische Universität Dresden | 133 | 2016-06-01 | 2026-05-29 |
| Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia Arsenic Trioxide, Cytarabine, Dexamethasone - Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA | Phase 3 | Active not recruiting | Children's Oncology Group | 158 | 2015-07-21 | 2026-02-18 |
| Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia Arsenic Trioxide, Cytarabine, Diagnostic Laboratory Biomarker Analysis - Childhood Acute Promyelocytic Leukemia With PML-RARA, Myeloid Neoplasm | Phase 3 | Completed | Children's Oncology Group | 106 | 2009-03-09 | 2022-10-25 |
| Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia Arsenic trioxide, Low-dose cytarabine alone - Acute Myeloid Leukemia | Phase 3 | Terminated | Cephalon | 67 | 2007-10-01 | 2012-08-01 |
| Phase III Trial in Acute Promyelocytic Leukemia Patients arsenic trioxide, idarubicin, mercaptopurine - Leukemia | Phase 3 | Completed | Gruppo Italiano Malattie EMatologiche dell'Adulto | 276 | 2007-08-01 | 2022-10-12 |
| Acute Promyelocytic Leukemia 2006 (APL) Arsenic trioxide, ATRA - Leukemia, Promyelocytic, Acute | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 800 | 2006-10-01 | 2014-04-16 |
| Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes alemtuzumab, arsenic trioxide, azacitidine - Leukemia, Myelodysplastic Syndromes | Phase 2 / Phase 3 | Completed | The University of New South Wales | 2000 | 2006-08-01 | 2013-08-26 |
| Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia tretinoin, daunorubicin hydrochloride, cytarabine - Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Promyelocytic Leukemia (M3) | Phase 3 | Completed | National Cancer Institute (NCI) | 420 | 1999-06-01 | 2013-06-05 |
Leukemia, Promyelocytic, Acute (7) · Leukemia (4) · Leukemia, Myeloid, Acute (2) · Myelodysplastic Syndromes (2) · Anemia, Refractory, with Excess of Blasts (1) · Congenital Abnormalities (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Leukemia, Basophilic, Acute (1) · Leukemia, Eosinophilic, Acute (1) · Leukemia, Erythroblastic, Acute (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Megakaryoblastic, Acute (1) · Leukemia, Monocytic, Acute (1) · Leukemia, Myelomonocytic, Acute (1)
Children's Oncology Group (2) · Assistance Publique - Hôpitaux de Paris (1) · Cephalon (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Li Junmin (1) · National Cancer Institute (NCI) (1) · Peking University People's Hospital (1) · Quetzal Therapeutics (1) · SDK Therapeutics, Inc. (1) · Technische Universität Dresden (1) · The University of New South Wales (1)
United States (5) · Canada (3) · France (3) · Italy (3) · China (2) · Germany (2) · Puerto Rico (2) · Spain (2) · Australia (1) · Austria (1) · Netherlands (1) · New Zealand (1) · Romania (1) · Saudi Arabia (1) · United Kingdom (1)
Alan K. Burnett, MD, FRCP (1) · Bayard Powell (1) · Francesco Lo Coco, MD (1) · Huaiyu Wang, Dr. (1) · John J Gregory (1) · Lu Min (1) · Matthew A Kutny (1) · Uwe Platzbecker, Prof. Dr. (1) · Xiao-Jun Huang, Doctor (1) · Zhang Sujiang (1)
PMID 23841729, PMID 20705755, PMID 24127444, PMID 25245446, PMID 25470713, PMID 27400939, PMID 30026341, PMID 31898521, PMID 34762093, PMID 39506905, PMID 40825164
2025 (2), U10CA031946 (1), U10CA098543 (1), U10CA180886 (1)